Search

Your search keyword '"Shidasp Siami"' showing total 4 results
Start Over Author "Shidasp Siami" Publisher springer science and business media llc
4 results on '"Shidasp Siami"'

1. Correction to: Infection-related ventilator-associated complications in ICU patients colonised with extended-spectrum β-lactamase-producing Enterobacteriaceae

Author

François, Barbier, Sébastien, Bailly, Carole, Schwebel, Laurent, Papazian, Élie, Azoulay, Hatem, Kallel, Shidasp, Siami, Laurent, Argaud, Guillaume, Marcotte, Benoît, Misset, Jean, Reignier, Michaël, Darmon, Jean-Ralph, Zahar, Dany, Goldgran-Toledano, Étienne, de Montmollin, Bertrand, Souweine, Bruno, Mourvillier, Jean-Francois, Timsit, and Sophie, Letrou

Subjects
Critical Care and Intensive Care Medicine
Abstract

The members of the OUTCOMEREA Study Group were provided in such a way that they could not be indexed as collaborators on PubMed. The publisher apologizes for this error and is pleased to list the members of the group here.

Published
2018
Full Text
View/download PDF

3. [Untitled]

Author

Jean-Paul Mira, Jean-Daniel Chiche, Shidasp Siami, and Jean-FrançDois Dhainaut

Subjects
Microbiology (medical), Septic shock, medicine.medical_treatment, Inflammation, Biology, Critical Care and Intensive Care Medicine, medicine.disease, Proinflammatory cytokine, Pathogenesis, Sepsis, Immune system, Cytokine, Immunology, medicine, Genetic variability, medicine.symptom
Abstract

Cytokines are key regulators of the host response to infection, controlling the inflammatory reaction which is an essential component of the defense mechanisms. The major importance of these proteins in the pathogenesis and outcome of infectious diseases has been clearly demonstrated. In humans, there is increasing evidence that the host's cytokine response is genetically determined and that the genetic variability of cytokines underlies the complexity of interindividual differences in the immune response to micro organism invasions. We review the influence of host cytokine gene on the susceptibility to and the severity of parasitic, bacterial and viral infections. Proinflammatory cytokine polymorphisms are discussed in detail because of their importance in the course of severe infections such as meningococcal disease, cerebral malaria and septic shock. Genetic variants of the IL-10 gene, an antiinflammatory cytokine appear to be responsible for an uncontrolled and intense CARS and may have also dramatic consequences as an overwhelming inflammatory response. Our greater understanding of the genetic factors that influence mortality and morbidity of infectious diseases will permit identification of genomic markers which may be required for risk stratification of patients targeted for novel immunomodulatory treatments helping clinicians to select the most appropriate treatment options for their patients.

Published
2001
Full Text
View/download PDF

4. Valproic acid as adjuvant treatment for convulsive status epilepticus: a randomised clinical trial

Author

Sharshar, Tarek, Porcher, Raphaël, Asfar, Pierre, Grimaldi, Lamiae, Jabot, Julien, Argaud, Laurent, Lebert, Christine, Bollaert, Pierre Édouard, Harlay, Marie Line, Chillet, Patrick, Maury, Éric, Santoli, Francesco, Blanc, Pascal, Sonneville, Romain, Vu, Dinh Chuyen, Rohaut, Benjamin, Mazeraud, Aurélien, Alvarez, Jean Claude, Navarro, Vincent, Clair, Bernard, Outin, Hervé D., Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Hôtel-Dieu [Paris], Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], Centre hospitalier Félix-Guyon [Saint-Denis, La Réunion], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Lorraine (UL), Hôpital de Hautepierre [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Hôpital de Châlons-en-Champagne, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Hôpital Robert Ballanger [Aulnay-sous-Bois], Centre Hospitalier René Dubos [Pontoise], Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier d'Etampes, Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Perception et Mémoire / Perception and Memory, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Infection et inflammation (2I), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Raymond Poincaré [Garches], Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy], and Valse investigators and for the Groupe d’Explorations Neurologiques en Reanimation (GENER): Laurent Argaud, Eric Azabou, François Beloncle, Omar Ben-Hadj, Pascal Blanc, Pierre-Edouard Bollaert, Francis Bolgert, Lila Bouadma, Patrick Chillet, Bernard Clair, Philippe Corne, Raphaël Clere-Jehl, Martin Cour, Arielle Crespel, Véronique Déiler, Jean Dellamonica, Sophie Demeret, Marie-Line Harley, Matthieu Henry-Lagarrigue, Julien Jabot, Nicholas Heming, Romain Hernu, Achille Kouatchet, Christine Lebert, Nicolas Lerolle, Eric Maury, Sophie Letrou, Aurélien Mazeraud, Alain Mercat, Satar Mortaza, Bruno Mourvillier, Hervé Outin, Catherine Paugham-Burtz, Marc Pierrot, Marion Provent, Benjamin Rohaut, Sylvie De La Salle, François Santoli, Maleka Schenk, Shidasp Siami, Vincent Souday, Tarek Sharshar, Romain Sonneville, Jean-François Timsit, Marie Thuong, Nicolas Weiss

Subjects
[SDV]Life Sciences [q-bio], Generalised convulsive status epilepticus, Valproic acid, Intensive care unit, Critical Care and Intensive Care Medicine, Seizure
Abstract

Background Generalised convulsive status epilepticus (GCSE) is a medical emergency. Guidelines recommend a stepwise strategy of benzodiazepines followed by a second-line anti-seizure medicine (ASM). However, GCSE is uncontrolled in 20–40% patients and is associated with protracted hospitalisation, disability, and mortality. The objective was to determine whether valproic acid (VPA) as complementary treatment to the stepwise strategy improves the outcomes of patients with de novo established GCSE. Methods This was a multicentre, double-blind, randomised controlled trial in 244 adults admitted to intensive care units for GCSE in 16 French hospitals between 2013 and 2018. Patients received standard care of benzodiazepine and a second-line ASM (except VPA). Intervention patients received a 30 mg/kg VPA loading dose, then a 1 mg/kg/h 12 h infusion, whilst the placebo group received an identical intravenous administration of 0.9% saline as a bolus and continuous infusion. Primary outcome was proportion of patients discharged from hospital by day 15. The secondary outcomes were seizure control, adverse events, and cognition at day 90. Results A total of 126 (52%) and 118 (48%) patients were included in the VPA and placebo groups. 224 (93%) and 227 (93%) received a first-line and a second-line ASM before VPA or placebo infusion. There was no between-group difference for patients hospital-discharged at day 15 [VPA, 77 (61%) versus placebo, 72 (61%), adjusted relative risk 1.04; 95% confidence interval (0.89–1.19); p = 0.58]. There were no between-group differences for secondary outcomes. Conclusions VPA added to the recommended strategy for adult GCSE is well tolerated but did not increase the proportion of patients hospital-discharged by day 15. Trial registration No. NCT01791868 (ClinicalTrials.gov registry), registered: 15 February 2012.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results